Your browser doesn't support javascript.
loading
Efficacy of Phase I and Phase II Coxiella burnetii Bacterin Vaccines in a Pregnant Ewe Challenge Model.
Williams-Macdonald, Sarah E; Mitchell, Mairi; Frew, David; Palarea-Albaladejo, Javier; Ewing, David; Golde, William T; Longbottom, David; Nisbet, Alasdair J; Livingstone, Morag; Hamilton, Clare M; Fitzgerald, Stephen F; Buus, Søren; Bach, Emil; Dinkla, Annemieke; Roest, Hendrik-Jan; Koets, Ad P; McNeilly, Tom N.
Afiliación
  • Williams-Macdonald SE; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Mitchell M; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Frew D; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Palarea-Albaladejo J; Biomathematics and Statistics Scotland, JCMB, The King's Buildings, Peter Guthrie Tait Road, Edinburgh EH9 3FD, UK.
  • Ewing D; Biomathematics and Statistics Scotland, JCMB, The King's Buildings, Peter Guthrie Tait Road, Edinburgh EH9 3FD, UK.
  • Golde WT; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Longbottom D; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Nisbet AJ; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Livingstone M; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Hamilton CM; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Fitzgerald SF; Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
  • Buus S; Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK 2200 Copenhagen, Denmark.
  • Bach E; Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK 2200 Copenhagen, Denmark.
  • Dinkla A; Department of Bacteriology, Host-Pathogen Interaction and Diagnostics, Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands.
  • Roest HJ; Department of Bacteriology, Host-Pathogen Interaction and Diagnostics, Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands.
  • Koets AP; Department of Bacteriology, Host-Pathogen Interaction and Diagnostics, Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands.
  • McNeilly TN; Department of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3584 CL Utrecht, The Netherlands.
Vaccines (Basel) ; 11(3)2023 Feb 22.
Article en En | MEDLINE | ID: mdl-36992095
The bacterium Coxiella burnetii can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of C. burnetii to humans; however, the only existing livestock vaccine, namely, Coxevac® (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I C. burnetii strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac® and an experimental bacterin vaccine based on phase II C. burnetii against C. burnetii challenge. Prior to mating, ewes (n = 20 per group) were vaccinated subcutaneously with either Coxevac®, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes (n = 6) from each group was then challenged 151 days later (~100 days of gestation) with 106 infectious mouse doses of C. burnetii, Nine-Mile strain RSA493. Both vaccines provided protection against C. burnetii challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac® can protect ewes against C. burnetii infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article Pais de publicación: Suiza